ArticleMolecular biology reports2025
TPX2 promotes ferroptosis in LPS-induced C28/I2 chondrocytes via NF-κB p65-mediated downregulation of GPX4 and SLC7A11.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on the mechanism of chondrocyte ferroptosis in osteoarthritis.Frontiers in immunology · 2026Review
- Glutathione peroxidase 4 as an emerging therapeutic target in osteoarthritis: focus on ferroptosis.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a progressive joint disorder characterized by cartilage degradation and increased oxidative stress. Recently, OA pathogenesis has been related to ferroptosis, an iron-dependent programmed cell death associated with oxidative damage. However, its regulatory mechanisms remain unclear. We sought to clarify the involvement of Targeting Protein for Xklp2 (TPX2) in ferroptosis regulation and its interaction with the nuclear factor kappa-light-chain-enhancer of activated B cells p65 subunit (NF-κB p65) pathway in OA.
methodsTo mimic OA conditions in vitro, C28/I2 chondrocytes were incubated with 5 µg/mL Lipopolysaccharide (LPS) for a 24-hour period. Intracellular iron levels (Fe²⁺, Fe³⁺, total iron) were measured using colorimetric assays. Glutathione peroxidase (GSH-Px) activity and glutathione (GSH/GSSG) levels were determined. Mitochondrial morphology was examined by transmission electron microscopy. Key ferroptosis markers (Solute Carrier Family 7 Member 11, SLC7A11; Glutathione Peroxidase 4, GPX4) were analyzed at the mRNA and protein levels. Cellular responses were evaluated utilizing cell counting kit-8 (CCK-8) viability assays, 5-Ethynyl-2'-deoxyuridineb (EdU) proliferation staining, and flow cytometry.
resultsLPS treatment significantly increased intracellular iron accumulation while decreasing GSH-Px activity and GSH/GSSG levels, accompanied by characteristic mitochondrial damage. TPX2 expression was significantly elevated in LPS-induced chondrocytes, whereas TPX2 knockdown reversed ferroptosis-related biochemical alterations and restored GPX4 and SLC7A11 expression via inhibition of NF-κB p65 phosphorylation. Moreover, NF-κB p65 overexpression attenuated these protective effects of TPX2 silencing. Ferroptosis activation by erastin abolished the protective effects conferred by TPX2 knockdown.
conclusionOur in vitro findings suggest that TPX2 may promote ferroptosis in LPS-induced C28/I2 chondrocytes via NF-κB p65 signaling, reducing antioxidant defenses. Further in vivo and clinical studies are needed to clarify its role and therapeutic potential in OA.
Indexed as
Identifiers
41369886What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.